Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.7663
+0.00270.35%
Pre-market: 0.7304-0.0359-4.68%08:06 EDT
Volume:89.69K
Turnover:68.34K
Market Cap:8.48M
PE:1.45
High:0.7850
Open:0.7850
Low:0.7200
Close:0.7636
Loading ...

PAVmed Inc expected to post earnings of $1.98 a share - Earnings Preview

Reuters
·
12 Nov 2024

Lucid Diagnostics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
11 Nov 2024

BRIEF-Lucid Diagnostics' Esoguard BE-1 Prospective Multicenter Clinical Validation Study Of Esoguard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication

Reuters
·
07 Nov 2024

Lucid Diagnostics' Esoguard Be-1 Prospective Multicenter Clinical Validation Study of Esoguard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

THOMSON REUTERS
·
07 Nov 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PR Newswire
·
07 Nov 2024

BRIEF-Lucid Diagnostics And Pavmed's Unit Embarked On Expansion Of Direct Contracting Initiative

Reuters
·
05 Nov 2024

Lucid Diagnostics: Co and PAVmed's Unit Embarked on Expansion of Direct Contracting Initiative

THOMSON REUTERS
·
05 Nov 2024

Press Release: Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Dow Jones
·
05 Nov 2024

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024

PR Newswire
·
31 Oct 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

PR Newswire
·
30 Oct 2024

Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test

seekingalpha
·
15 Oct 2024

BRIEF-Lucid Diagnostics Receives Notice Of Allowance For Key Patent Underlying Its Esoguard Esophageal DNA Test

Reuters
·
15 Oct 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its Esoguard Esophageal DNA Test

THOMSON REUTERS
·
15 Oct 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PR Newswire
·
15 Oct 2024

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million Nih Grant to Enhance Cancer Care

THOMSON REUTERS
·
10 Oct 2024

PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care

PR Newswire
·
10 Oct 2024